UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders

European psychiatry, 2024-08, Vol.67 (S1), p.S65-S66

2024

Volltextzugriff (PDF)

Psychotherapies for generalized anxiety disorder in adults: systematic review and network meta-analysis of randomized-controlled trials

European psychiatry, 2024-08, Vol.67 (S1), p.S50-S51

2024

Volltextzugriff (PDF)

Psychological and social interventions for the promotion of mental health in people living in low- and middle-income countries affected by humanitarian crises

Cochrane database of systematic reviews, 2024-05, Vol.5 (5), p.CD014300

2024

Volltextzugriff (PDF)

Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database

Psychological medicine, 2023-09, Vol.53 (12), p.5645-5653

2023

Volltextzugriff (PDF)

Pharmacovigilance analysis of the Vigibase on neonatal withdrawal syndrome following in utero exposure to antidepressants

European psychiatry, 2023-03, Vol.66 (S1), p.S96-S96

2023

Volltextzugriff (PDF)

Pharmacovigilance analysis of the Vigibase on antidepressants-related withdrawal syndrome in adults and adolescents

European psychiatry, 2023-03, Vol.66 (S1), p.S95-S96

2023

Volltextzugriff (PDF)

Have the COVID-19 outbreak and related restrictions affected the right to mental health of people with severe mental health conditions?

International review of psychiatry (Abingdon, England), 2023-02, Vol.35 (2), p.180-193

2023

Volltextzugriff (PDF)

Long-term effectiveness of Self-Help Plus in refugees and asylum seekers resettled in Western Europe: 12-month outcomes of a randomised controlled trial

Epidemiology and psychiatric sciences, 2022-06, Vol.31, p.e39-e39, Article e39

2022

Volltextzugriff (PDF)

Esketamine for treatment-resistant depression in adults

Cochrane database of systematic reviews, 2022-01, Vol.2022 (1)

2022

Volltextzugriff (PDF)

Safety of psychotropic medications in people with COVID-19

European psychiatry, 2021-04, Vol.64 (S1), p.S93-S93

2021

Volltextzugriff (PDF)

Which psychotherapy is effective in panic disorder? Findings and reflections from a systematic network meta-analysis

European psychiatry, 2021-04, Vol.64 (S1), p.S118-S118

2021

Volltextzugriff (PDF)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market

European psychiatry, 2021-04, Vol.64 (S1), p.S150-S151

2021

Volltextzugriff (PDF)

Esketamine for treatment resistant depression: a trick of smoke and mirrors?

Epidemiology and psychiatric sciences, 2020-01, Vol.29, p.e79-e79, Article e79

2020

Volltextzugriff (PDF)

Poor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries

Epidemiology and psychiatric sciences, 2020-01, Vol.29, p.e126-e126, Article e126

2020

Volltextzugriff (PDF)

Esketamine clinical trials: reply to Maju et al

Epidemiology and psychiatric sciences, 2020-01, Vol.29, p.e122-e122, Article e122

2020

Volltextzugriff (PDF)

Antipsychotic use and risk of life‐threatening medical events: umbrella review of observational studies

Acta psychiatrica Scandinavica, 2019-09, Vol.140 (3), p.227-243

2019

Volltextzugriff (PDF)

Efficacy and acceptability of antidepressants for the treatment of depressive symptoms in adult patients with ischemic heart disease

Journal of psychosomatic research, 2018-06, Vol.109, p.141-142

2018

Volltextzugriff (PDF)

Can a digital medicine system improve adherence to antipsychotic treatment?

Epidemiology and psychiatric sciences, 2018-06, Vol.27 (3), p.227-229

2018

Volltextzugriff (PDF)

Antipsychotic combinations in schizophrenia

Epidemiology and psychiatric sciences, 2017-10, Vol.26 (5), p.462-465

2017

Volltextzugriff (PDF)

New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base

Epidemiology and psychiatric sciences, 2017-06, Vol.26 (3), p.231-233

2017

Volltextzugriff (PDF)

Antipsychotic drug exposure and risk of myocardial infarction

Epidemiology and psychiatric sciences, 2017-02, Vol.26 (1), p.18-21

2017

Volltextzugriff (PDF)

Genetics and Autosomal Dominant Polycystic Kidney Disease Progression

Contributions to nephrology, 2017-01, Vol.190, p.117

2017

Volltextzugriff (PDF)

First-generation antipsychotics and QTc: any role for mediating variables?

Human psychopharmacology, 2016-07, Vol.31 (4), p.313-318

2016

Volltextzugriff (PDF)

Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval

PloS one, 2016-02, Vol.11 (2), p.e0148212-e0148212

2016

Volltextzugriff (PDF)

Drug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine

Acta psychiatrica Scandinavica, 2015-06, Vol.131 (6), p.408-416

2015

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(46)

Sprache

Englisch
(44)
Italienisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(30)
Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Psychiatry
(15)
Psychotropic Drugs
(10)
Female
(9)
Adult
(8)
Antidepressants
(8)
Aged
(7)
Antipsychotics
(7)
Male
(7)
Middle Aged
(7)
Transplantation
(7)
Urology & Nephrology
(7)
Engineering
(6)
Engineering, Biomedical
(6)
Epidemiology For Clinical Psychopharmacology
(6)
Mental Disorders
(6)
Mental Health
(6)
Psychopharmacology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders

Psychotherapies for generalized anxiety disorder in adults: systematic review and network meta-analysis of randomized-controlled trials

Psychological and social interventions for the promotion of mental health in people living in low- and middle-income countries affected by humanitarian crises

Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database

Pharmacovigilance analysis of the Vigibase on neonatal withdrawal syndrome following in utero exposure to antidepressants

Pharmacovigilance analysis of the Vigibase on antidepressants-related withdrawal syndrome in adults and adolescents

Have the COVID-19 outbreak and related restrictions affected the right to mental health of people with severe mental health conditions?

Long-term effectiveness of Self-Help Plus in refugees and asylum seekers resettled in Western Europe: 12-month outcomes of a randomised controlled trial

Esketamine for treatment-resistant depression in adults

Safety of psychotropic medications in people with COVID-19

Which psychotherapy is effective in panic disorder? Findings and reflections from a systematic network meta-analysis

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market

Esketamine for treatment resistant depression: a trick of smoke and mirrors?

Poor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries

Esketamine clinical trials: reply to Maju et al

Antipsychotic use and risk of life‐threatening medical events: umbrella review of observational studies

Efficacy and acceptability of antidepressants for the treatment of depressive symptoms in adult patients with ischemic heart disease

Can a digital medicine system improve adherence to antipsychotic treatment?

Antipsychotic combinations in schizophrenia

New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base

Antipsychotic drug exposure and risk of myocardial infarction

Genetics and Autosomal Dominant Polycystic Kidney Disease Progression

First-generation antipsychotics and QTc: any role for mediating variables?

Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval

Drug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine

Suchergebnisse filtern